Observation On The Effects Of Mosapride Combined With Probiotics Of Clostridium Butyricum And Bifidobacterium Infantis In Preventing Feeding Intolerance In Preterm Infants

【Objective】To evaluate the clinical efficacy of gastrointestinal motility drug Mosapride combinedwith probiotics of Clostridium butyricum and bifidobacterium infantis power ofrpreventing feeding intolerance (Fl) in premature infants.【Methods】448premature infants were admitted in NICU of the First Aiffliated hospital of BengbuMedical College from January2007to June2012. The inclusion criteria included:(1)gestational age<37weeks of live birth infants.(2)^24h after birth that admission. Theexclusion criteria included： consenital sastrointestiiial malformations，neonatal hemorrhasicdisease，severe asphyxia and neonatalrespi ratory distress syndrome. A total of448preterminfants met the mclusion criteria. An individual was included into group A if entering hospital duringI-1Ost day per month (the conventional group): totally comprising of104cases; group B (theprobiotics group) is consisted of173cases according to the date of entering in to hospital duirngII-20srper month and group C (the probiotics-Mosapirde group) is consisted of171casesaccording ro the date of enteirng in to hospital during21-30st per month. Infants of group A weregiven general care and treatment. Based on group A，probiotics of Clostridium butyricum andbifidobacterium inefntis was administered orally or via a orogastric tube ro infants m group B within6hours after birth,0.25g，twice daily. Group C were given gastrointestinal motility drug Mosapridebased on group A orally or via a orogastric tube within6hours after birth?0.2mg/kg，3times a day.Observe and record the incidence of feeding intolerance，duration of feeding intolerance,thedecreasing margin of body weight, the time to return to birth weight, the time to reach ifill gastromtestinal feeding and hospital stay, et al. All data were analyzed using SPSS18.0sotfware. Measurement data are presented as mean土standard deviation and count datato rate (%)?Using analysis of variance and the q test and chi-square test, P <0.05wasconsidered statistically significant.【Results】The incidence of feeding intolerance of group B and group C were lower than group A(P <0.01), duration of feeding intolerance were shorter than that in group A (P <0.01); the body weight decrease atfer birth were lower than group A (P <0.01)，andtime to reach the birth body weight, to reach full enteral feeding and hospital stay wereshorter in group A (P <0.05—P <0.01)，body weight growth were greater than groupA (P <0.01). The incidence of feeding intolerance in group C and group B there wasno statistically significant difference (P>0.05)，In group C，duration of feedingintolerance, time to reach the birth body weight, to reach ofil enteral feeding andhospital stay were shorter than group B (尸<0.05?尸<0.01)，the body weightdecrease atfer birth was lower than group B (尸<0.01)，body weight growth was fasterthan group B (P <0.01). There were no adverse reactions were observed in applicationprocess of Mosapride and probiotics of Clostridium biityricum and bifidobacteriuminfantis.【Conclusions】Gastrointestinal motility drug Mosapride combined with probiotics of Clostridiumbutyricum and bifidobacterium infantis can effectively prevent and treat premature infantswith feeding intolerance, better than singly use of probiotics of Clostridium butyricum andbifidobacterium infantis, can facilitate the early growth of premature infants and shortenthe time to reach full enteral feeding.